United States News Todas as matérias

Takeda (NYSE:TAK) announced Phase 3 LATITUDE study results for investigational drug zasocitinib (TAK-279), reporting statistically significant improvements compared with deucravacitinib in adults with moderate-to-severe plaque psoriasis.

AbbVie (NYSE:ABBV) announced that it will present 60 dermatology research abstracts, including three late-breaking presentations, at the 2026 European Academy of Dermatology and Venereology (EADV) Congress in Vienna, Austria, covering multiple immune-mediated skin diseases.

Amentum (NYSE:AMTM) has been selected by United Kingdom nuclear site operator Sellafield as preferred supplier for a Projects and Asset Care Execution (PACE) framework contract valued at up to £2.1 billion ($2.78 billion).

AbbVie (NYSE:ABBV) reported positive Phase 2 APEX Part B study results for zumilokibart, with all three tested dose regimens achieving the primary endpoint among 346 adults with moderate to severe atopic dermatitis.

Tesla (NASDAQ:TSLA) is preparing to release its third-quarter 2026 delivery figures, with investors watching closely for signs of demand momentum amid a more competitive electric vehicle market.

L3Harris Technologies (NYSE:LHX) announced that it received an undefinitized contract from Lockheed Martin valued at more than $6 billion, excluding escalations, over seven years to expand propulsion production for the Terminal High Altitude Area Defense (THAAD) missile defense system.

Oncolytics Biotech (NASDAQ:ONCY) reported published preclinical findings showing that pelareorep increased markers associated with immune activation in hepatocellular carcinoma (HCC), the most common form of liver cancer.

Cosmos Health (NASDAQ:COSM) reported record second-quarter 2026 revenue exceeding $15 million at its CosmoFarm pharmacy distribution subsidiary.

Carnival Corporation (NYSE:CCL) reported third-quarter 2026 financial results, with record revenue and stronger operating expectations for the full year.

Propanc Biopharma (NASDAQ:PPCB) reported fiscal 2026 financial results and provided an update on development plans for PRP, its investigational cancer therapy candidate.

Lite Strategy (NASDAQ:LITS) reported fiscal 2026 results for the year ended June 30, marking its first fiscal year operating under a Litecoin treasury strategy.

1-800-FLOWERS.COM (NASDAQ:FLWS) announced a definitive agreement to sell PersonalizationMall.com and Things Remembered to PlanetArt, LLC for approximately $45 million in cash.

Iovance Biotherapeutics (NASDAQ:IOVA) raised its full-year 2026 revenue guidance following stronger-than-expected demand for its commercial products, Amtagvi and Proleukin.

Nurix Therapeutics (NASDAQ:NRIX) announced that it achieved a $7 million research milestone under its collaboration with Pfizer (NYSE:PFE) to develop degrader antibody conjugates.

BeyondSpring (NASDAQ:BYSI) announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to Plinabulin in combination with docetaxel for previously treated advanced non-squamous lung cancer.

BIO-key (NASDAQ:BKYI) announced a partnership with Al Majlis Group to introduce its identity security platform to organizations in the United Arab Emirates and Saudi Arabia.

Immix Biopharma (NASDAQ:IMMX) reported interim results from its Phase 2 NEXICART-2 clinical trial evaluating NXC-201 in patients with relapsed or refractory AL amyloidosis.

Turbo Energy (NASDAQ:TURB) reported first-half 2026 financial results, with significant revenue growth and a return to profitability.

Johnson & Johnson (NYSE:JNJ) reported two-year findings for IMAAVY in adolescents with generalized myasthenia gravis (gMG), along with results from a retrospective survey evaluating adults who switched to the therapy from other advanced treatments.

Caterpillar (NYSE:CAT) announced an agreement to acquire John Fabick Tractor Company, an independent Cat dealer serving customers across parts of the Midwest United States.

PowerBank (NASDAQ:PBK) reported fiscal 2026 financial results, with lower revenue but improved gross margins and a narrower net loss.

SLB (NYSE:SLB) announced that its OneSubsea joint venture has been awarded a contract by ExxonMobil Moçambique, Limitada, on behalf of its Area 4 partners, to deliver subsea production systems for the first phase of the offshore Rovuma LNG project in Mozambique.

Aldeyra Therapeutics (NASDAQ:ALDX) announced plans to submit a Formal Dispute Resolution Request (FDRR) to the U.S. Food and Drug Administration (FDA) seeking review of the agency’s decision not to approve reproxalap, its investigational therapy for dry eye disease.

Unicycive Therapeutics (NASDAQ:UNCY) resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration for oxylanthanum carbonate, an investigational treatment for hyperphosphatemia in patients receiving dialysis.